This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Dihydroberberine
Dihydroberberine (DHB) is the reduced, gut-absorbable form of berberine — same isoquinoline alkaloid scaffold, with the C=N+ iminium bond reduced to a neutral tertiary amine.
Aliases (4)
Overview
What is Dihydroberberine?
Dihydroberberine (DHB) is the reduced/dihydro analog of berberine, an isoquinoline alkaloid extracted from Berberis spp. and Coptis chinensis. Sold OTC as a supplement (often as 'GlucoVantage', sometimes labeled dihydroberberine sulfate). Approximately 5x higher oral bioavailability than parent berberine because DHB bypasses the gut-microbial reduction step that limits berberine absorption. NOT to be confused with dihydroboldenone (also abbreviated 'DHB'), which is an entirely separate anabolic steroid (1-testosterone) with no metabolic-health relevance.
Key Benefits
Activates AMPK (the same hepatic energy-sensor pathway as metformin and parent berberine) to lower fasting glucose, improve insulin sensitivity, reduce HOMA-IR, and modestly improve lipid panels (lowered LDL and triglycerides, mildly raised HDL in some trials). Remodels gut microbiome toward higher Akkermansia and SCFA-producing taxa. Major practical advantage over regular berberine: dramatically lower GI side-effect burden (no diarrhea, less constipation, no acute motility hit) at therapeutic dose because DHB is absorbed directly rather than requiring high gut-luminal berberine concentrations to drive bacterial reduction.
Mechanism of Action
Pan 2010 (Drug Metabolism and Disposition) established that orally dosed berberine is a poor systemic drug — it gets reduced by gut bacterial nitroreductases to dihydroberberine in the lumen, DHB is absorbed across the enterocyte, then re-oxidized back to berberine in the gut wall and liver to enter systemic circulation. Direct DHB dosing short-circuits the rate-limiting bacterial step, raising plasma berberine equivalents ~5x. Once systemic, the molecule activates AMPK via partial inhibition of mitochondrial complex I (similar mechanism to metformin), suppressing hepatic gluconeogenesis, lowering lipogenesis, and improving peripheral glucose uptake. Brusq 2006 confirmed direct AMPK activation as the mechanism for berberine's lipid and glucose effects.
Pharmacokinetics
Peptide Interactions
Complementary insulin-sensitization. ALA improves muscle-level glucose disposal via PDH activation and mitochondrial antioxidant support; DHB suppresses hepa…
Modest additive fasting glucose effect via cinnamaldehyde insulin-receptor sensitization. Cheap; mild signal. Note coumarin content in cassia variety — if us…
Insulin-sensitization adjunct, especially relevant in PCOS or insulin-resistant women. Different mechanism (post-receptor insulin signaling) — complementary …
Modest insulin-sensitizing effect; weak as standalone but reasonable add for metabolic-syndrome targeting.
Lipid-panel synergy — DHB lowers TG and LDL, omega-3 lowers TG further and shifts particle size favorably. Independent anti-inflammatory.
Additive anti-inflammatory + lipid-lowering. Both are AMPK activators in different tissues.
General metabolic-health stack; D3 broadly insulin-sensitizing; no direct mechanism overlap but consistent biomarker improvements in stacking trials.
Insulin-sensitizing in deficient individuals; broad metabolic-health support.
Pointless and arguably counterproductive — DHB IS the absorbed berberine pool. Pick one. DHB wins on tolerability and (claimed) dose-economy; parent berberin…
Mechanistically redundant (both AMPK activators). Stacking is theoretically additive on glycemia but rarely indicated. The Yang 2025 rat study (PMC12093149) …
(cyclosporine, tacrolimus, simvastatin/lovastatin, certain calcium channel blockers, midazolam, alprazolam at high dose, some antiarrhythmics): see Drug Inte…
(digoxin, dabigatran, apixaban, rivaroxaban, edoxaban): see Drug Interactions.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (dramatically less than parent berberine):
- Mild bloating or stool change in first 1-2 weeks (~10-15% of users by community report). Usually resolves.
- Mild constipation in a minority (opposite signal from parent berberine's diarrhea pattern).
- Less common:
- Mild appetite reduction (some users count as feature, not bug).
- Mild headache or fatigue first week — typically resolves.
- Less common, watch:
- Brain fog / cognitive blunting — documented as ~15-25% in chronic parent-berberine community data; DHB-specific rate unclear, likely lower if gut-flora-mediated. Stop if persists >2-3 weeks.
- Insomnia with evening dosing — uncommon, but reason to dose before 4 PM if susceptible.
- Photosensitivity — rarely reported with parent berberine; mechanistically possible for DHB.
- Rare-serious:
- Hypoglycemia — rare as monotherapy in healthy/lean users; meaningful when combined with insulin or sulfonylureas. Adjust antidiabetic doses if stacking. Particularly relevant for T2D patients adding DHB to existing regimen.
- Hepatotoxicity — case reports exist for high-dose chronic berberine (>2 g/day parent); DHB-specific rate unclear, likely proportional to systemic exposure. Baseline + 12-week ALT/AST check is reasonable.
- Manic / activation symptoms — flagged in parent berberine community data (rare, mechanism speculative — possibly gut-flora-mediated 5-HT changes in vulnerable individuals). DHB-specific data sparse.
- Allergic reaction / dermatitis — case reports exist, rare.
- Specific watch periods:
- Weeks 1-2: GI tolerability — should be much better than parent berberine; if GI signal is severe, suspect product mislabeling (parent berberine sold as DHB) and verify COA.
- Weeks 8-12: Biomarker checkpoint — HbA1c, FPG, fasting insulin, lipids, ALT/AST. Decide continuation.
- Pregnancy / breastfeeding: ABSOLUTE CONTRAINDICATION. Berberine displaces bilirubin from serum albumin (~10× more potently than phenylbutazone in vitro). Crosses the placenta. Risk of fetal/neonatal kernicterus — bilirubin-induced brain damage. Also reported uterotonic effect in animal studies. DHB is rapidly re-oxidized to berberine in tissues, so the same hazard applies — there is no plausible mechanism by which DHB would be safe in pregnancy when berberine isn't. Absolute contraindication. Discontinue ≥1 month before planned conception as a precautionary measure (no formal washout data; some practitioners say 3 months).
- Neonates and infants: Same bilirubin-displacement mechanism. Do not administer.
- Liver disease: Caution / avoid in active hepatic impairment. Berberine and DHB both undergo hepatic metabolism; impaired liver function elevates systemic exposure unpredictably. The CYP3A4 inhibition surface also compounds risk if other medications are on board.
- Hypoglycemia history or active glycemic instability: Use cautiously; adjust co-meds.
- Pre-surgical: Discontinue ≥1 week before any surgery / anesthesia given the CYP3A4 inhibition (most anesthetic agents are CYP3A4 substrates) and theoretical bleeding-risk additivity with anticoagulants.
References
Moon JM et al. 2021 — Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial (Nutrients, PMID 35010998)
the only human DHB PK study; n=5, single-dose, 7× AUC for 100 mg DHB vs 500 mg parent berberine.
View StudyFeng R et al. 2015 — Transforming berberine into its intestine-absorbable form by the gut microbiota (Sci Rep, PMID 26174047)
established gut bacterial nitroreductase conversion of berberine to DHB as the actual absorption pathway. Mechanistic foundation for direct DHB dosing.
View StudyPan GY et al. 2002 — The involvement of P-glycoprotein in berberine absorption (Pharmacol Toxicol, PMID 12530470)
P-glycoprotein efflux as rate-limiting in berberine absorption. Note: marketing literature often miscites a 2010 Drug Metab Dispos paper that doesn't exist; this 2002 paper is the original.
View StudyYin J, Xing H, Ye J 2008 — Efficacy of berberine in patients with type 2 diabetes mellitus, head-to-head with metformin (Metabolism, PMID 18442638)
foundational 36-patient RCT; metformin-equivalent HbA1c reduction.
View StudyCao C et al. 2024 — Effects of administering berberine alone or in combination on type 2 diabetes mellitus, systematic review and meta-analysis (Front Pharmacol, PMID 39640489)
50 RCTs, 4150 patients; combined HbA1c -0.69%.
View StudySun R et al. 2024 — Clinical efficacy and safety of berberine in NAFLD: meta-analysis (J Transl Med, PMID 38429794)
10 RCTs, 811 patients; ALT/AST/HOMA-IR significantly improved.
View StudyTang J et al. 2025 — Efficacy and safety of berberine on components of metabolic syndrome (Front Pharmacol, PMC12307485)
12 placebo-controlled RCTs, 889 patients; TG -0.37, FPG -0.52, waist -3.27 cm.
View StudyBrusq JM et al. 2006 — Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine (J Lipid Res, PMID 16508037)
AMPK activation mechanism paper.
View StudyKong W et al. 2004 — Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins (Nat Med, PMID 15531889)
foundational LDLR / cholesterol mechanism. -29% TC, -25% LDL, -35% TG.
View StudyFogacci F et al. 2022 — Berberine: ins and outs of a nature-made PCSK9 inhibitor (EXCLI J, PMID 36381647)
modern PCSK9 mechanism review.
View StudyGuo Y et al. 2012 — Repeated administration of berberine inhibits cytochromes P450 in humans (Eur J Clin Pharmacol, PMID 21870106)
CYP3A4 midazolam AUC +40%; CYP2D6 dextromethorphan ratio +9-fold; CYP2C9 losartan ratio doubled.
View StudyWu X et al. 2005 — Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients (Eur J Clin Pharmacol, PMID 16133554)
cyclosporine trough +88.9% with berberine 200 mg TID × 3 mo.
View StudyKonopka AR et al. 2019 — Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults (Aging Cell, PMID 30548390)
metformin blunts aerobic mitochondrial adaptation.
View StudyWalton RG et al. 2019 — Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: MASTERS trial (Aging Cell, PMID 31557380)
metformin blunts resistance-training hypertrophy.
View StudyYan HM et al. 2015 — Efficacy of berberine in patients with non-alcoholic fatty liver disease (PLoS One, PMID 26252777)
berberine reduced hepatic fat content 52.7% vs pioglitazone 36.4%.
View StudyExamine.com — Berberine
neutral evidence-grade summary (parent compound; DHB inherits systemically).
View StudyGlucoVantage / NNB Nutrition — DHB technical brief
IP-holder formulator material. Marketing-leaning but the primary commercial source for verified DHB raw material.
View StudyMemorial Sloan Kettering — Berberine herb summary
clinical reference for cancer context (P-gp / CYP3A4 substrate warnings).
View StudyLatest research
- rctAbsorption kinetics of berberine and dihydroberberine and their impact on glycemia — randomized crossover pilot trialMoon et al. — n=5 healthy males, single-dose crossover. 100 mg DHB AUC ~284 ng·h/mL vs 500 mg standard berberine ~42 ng·h/mL — roughly 7× higher plasma exposure at 1/5 the dose. No glycemic difference between arms at single-dose OGTT. The only published human DHB PK trial. Underpowered (n=5), commercial-friendly design (NNB Nutrition material), no replication. This study IS the entire "5× bioavailability" marketing edifice.
- mechanismTransforming berberine into its intestine-absorbable form by the gut microbiotaFeng et al., Sci Rep — established that gut bacterial nitroreductases convert poorly-absorbed parent berberine into dihydroberberine, which is the actual species crossing the enterocyte membrane. DHB is then re-oxidized to berberine in tissues. Mechanistic basis for direct DHB dosing — skip the bacterial reduction bottleneck. Far stronger paper than the often-cited Pan 2002 P-glycoprotein study (PMID 12530470).
- rctEfficacy of berberine in patients with type 2 diabetes mellitusYin et al., Metabolism — 36 newly-diagnosed T2D patients, 3-month RCT. Berberine 500 mg TID vs metformin 500 mg TID. HbA1c 9.5% → 7.5% in both arms; FPG and TG comparable. Foundational human metformin-equivalence study for parent berberine; DHB inherits at lower mg by PK extrapolation, not by direct trial.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.